TY - BOOK ID - 134388788 TI - MicroRNA and Cancer PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Biology, life sciences KW - Breast cancer KW - Hypoxia inducible factor 1-alpha (HIF-1α) KW - MicroRNA (miRNA) KW - miR526b KW - miR655 KW - Oxidative stress KW - Migration KW - Cyclooxygenase-2 (COX-2) KW - Prostaglandin E2 receptor 4 (EP4) KW - PI3K/Akt KW - adipokines KW - endometrial cancer KW - estrogens KW - hyperinsulinemia KW - insulin KW - insulin resistance KW - insulin signaling KW - insulin-like growth factors KW - microRNA KW - miRNA KW - ovarian cancer KW - survival KW - prognostic factor KW - serum LDH KW - blood biomarker KW - circulating microRNA KW - plasma KW - immunotherapy KW - immune checkpoint inhibitors KW - metastatic melanoma KW - hepatocellular carcinoma KW - metastasis KW - exosome KW - bioinformatics analysis KW - renal cancer KW - RCC KW - ccRCC KW - meta-analysis KW - miRNAs KW - normal B-cell development KW - B-CLL KW - miRNA-transcription factor network KW - regulation KW - biomarker KW - therapy KW - prognosis KW - diagnosis KW - progression KW - prediction KW - smoking KW - non-small cell lung cancer KW - methylation KW - miR-584-5p KW - YKT6 KW - snoRNA KW - 2′-O-methylation KW - pseudouridylation KW - malignant melanoma KW - cancer stem cell KW - stemness KW - head and neck squamous cell carcinoma KW - colon cancer KW - cancer stem cells KW - microRNAs KW - deformability KW - PARP KW - replication stress KW - targeted therapy KW - breast cancer KW - circulating biomarkers KW - medulloblastoma KW - brain tumour KW - subgroups KW - stem cells KW - n/a KW - 2'-O-methylation UR - https://www.unicat.be/uniCat?func=search&query=sysid:134388788 AB - MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of “miR replacement therapy” to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs. ER -